Case No. 3:13-cv-03047-SI

# 2

1

# 4

# 5

# 6 7

# 8

#### 1.0

#### 1 1

#### . .

#### 12

# 13

# 15

# 16

# 17

### 18

# 19

### 20

# 21

# 22

#### 23

#### 24

# 25

# 27

### 28

Case No. 3:13-cv-03047-SI

-1 -

#### JOINT STIPULATION AND [PROPOSED] ORDER

Plaintiffs in this action, Defendant GlaxoSmithKline LLC, (f/k/a SmithKline Beecham Corporation d/b/a GlaxoSmithKline) ("GSK") and Defendant McKesson Corporation ("McKesson"), hereby submit, through their undersigned counsel of record, the following Stipulation and accompanying [Proposed] Order.

WHEREAS, Pursuant to Federal Rule of Civil Procedure 81(c)(2), Defendants GSK, and McKesson (collectively, "Defendants") have not yet answered the Plaintiffs' Complaint prior to removal of this case from San Francisco Superior Court on July 2, 2013. Defendants have 21 days after "receiving--through service or otherwise--a copy of the initial pleading stating the claim for relief" and therefore have 21 days to Answer Plaintiffs' Complaint. McKesson has not been served with Plaintiffs' Complaint. GSK has also not been served with Plaintiffs' Complaint. GSK filed a Motion to Stay on July 10, 2013. Plaintiffs filed a Motion to Remand on July 12, 2013. (*See* Declaration of Steven J. Boranian ("Boranian Decl.") in Support of Joint Stipulation Extending Defendants' time to Answer Complaint ¶ 7)

WHEREAS, the parties, having met and conferred, pursuant to Civil L.R 6-3, jointly stipulate to and respectfully request that this Court extend the time for Defendants to Answer the Complaint until 30 days after entry of an order on Plaintiffs' Motion to Remand. (*See* Boranian Decl. ¶ 8)

WHEREAS, the parties agree that good cause exists for the requested extension of time in order to serve the interests of judicial economy, efficiency, and fairness. This action will either be remanded to the Superior Court of San Francisco or transferred to the Avandia MDL. Therefore, in order to conserve the resources of the Court and the parties, all parties agree that Defendants' Answers should ultimately be filed should ultimately be filed in the San Francisco Superior Court or in the Avandia MDL. (*See* Boranian Decl. ¶ 9)

WHEREAS, no party to this case has previously requested any time modifications in this action. (See Boranian Decl.  $\P$  10)

By the filing of this Joint Stipulation and Proposed Order, the Plaintiffs do not concede, and

# **FILER'S ATTESTATION** 2 Pursuant to Local Rule 5-1(i)(3), the undersigned attests that all signatories have concurred in 3 the filing of this Joint Stipulation And [Proposed] Order Extending Time for Defendants to Answer Plaintiffs' Complaint. 5 6 DATED: July 17, 2013 REED SMITH LLP 7 Michael K. Brown Sonja S. Weissman 8 Steven J. Boranian 9 10 By: /s/ Steven J. Boranian Steven J. Boranian A limited liability partnership formed in the State of Delaware Attorneys for Defendants GlaxoSmithKline LLC (formerly known as SmithKline Beecham Corporation d/b/a 11 12 GlaxoSmithKline) and McKesson Corporation 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Case No. 3:13-cv-03047-SI

REED SMITH LLP  A limited liability partnership formed in the State of Delaware		1	
		1 2 3 4 5 6 7 8 9	
		3	
		4	
		5	
		6	
		7	
		8	
		9	
		10	
	nership formed in the State of Delaware	11	
		<ul><li>11</li><li>12</li><li>13</li><li>14</li><li>15</li><li>16</li><li>17</li><li>18</li></ul>	
		13	
		14	
	bility part	15	
	limited lia	16	
	∢	17	
		18	
		19	
		20	
		21	
		22	
		23	
		24	
		25	
		26	
		27	

#### [PROPOSED] ORDER

PURSUANT TO STIPULATION, IT IS SO ORDERED

DATED: \_\_\_\_\_7/19/13

Hanarahla Sugan Illatan

Case No. 3:13-cv-03047-SI

REED SMITH LLP
A limited liability partnership formed in the State of Delaware

1	Michael K. Brown (SBN 104252)				
2	Email: mkbrown@reedsmith.com				
2	Reed Smith LLP 355 South Grand Avenue				
3	Suite 2900				
4	Los Angeles, CA 90071-1514 Telephone: +1 213 457 8000				
	Facsimile: +1 213 457 8080				
5	Sonja S. Weissman (SBN 154320)				
6	Email: sweissman@reedsmith.com				
7	Steven J. Boranian (SBN 174183) Email: sboranian@reedsmith.com				
	Reed Smith LLP				
8	101 Second Street Suite 1800				
9	9 San Francisco, CA 94105-3659				
10	Telephone: +1 415 543 8700 Facsimile: +1 415 391 8269				
11	Attorneys for Defendants GlaxoSmithKline LLC (formerly known as				
12	SmithKline Beecham Corporation d/b/a				
13	GlaxoSmithKline) and McKesson Corporation				
	UNITED STATES DISTRICT COURT				
14					
15	NORTHERN DISTRICT OF CALIFORNIA				
16	RENETTA BARNES, Individually and as	Case No. 3:13-cv-03047-SI			
17	Successor-in-interest on behalf of the Estate of CLARA BURRELL-HARVELL, Deceased, et al.,				
1/		DECLARATION OF STEVEN J.			
18	Plaintiffs,	BORANIAN IN SUPPORT OF JOINT			
19	vs.	STIPULATION AND [PROPOSED] ORDER EXTENDING TIME FOR			
20	McKESSON CORPORATION, a corporation,	DEFENDANTS TO ANSWER			
	SMITHKLINE BEECHAM CORPORATION	COMPLAINT			
21	d/b/a GLAXOSMITHKLINE, and DOES ELEVEN through FIFTY, Inclusive,	Honorable Susan Illston			
22		Honorable Susan Histon			
23	Defendants,				
	VS.				
24	DOES FIFTY-ONE through ONE HUNDRED,				
25	Inclusive,				
26	Nominal Defendants for				
	Wrongful Death Action.				
27					
28	-				

1

2

3

5

7

9

10

11

13

14

16

17

19

21

22

23

26

28

#### I, Steven J. Boranian, declare:

- I am an attorney duly admitted to practice law in the State of California and a partner at Reed Smith LLP, counsel for defendant GlaxoSmithKline LLC ("GSK") and McKesson Corporation ("McKesson"). I have personal knowledge of the facts set forth in this declaration and for those matters for which I do not have personal knowledge, I am informed and believe they are true. I could and would testify to these matters if called as a witness.
- 2. A Multidistrict Litigation ("MDL") has been established in the Eastern District of Pennsylvania entitled In re Avandia® Marketing, Sales Practices, and Products Liability Litigation (MDL-1871), to coordinate all product liability cases involving alleged health risks from Avandia® (the "Avandia® cases").
- 3. The Avandia MDL is composed entirely of cases, like the instant case, seeking damages for injuries allegedly caused by Avandia.
  - 4. Over 7,800 cases have been filed in or already transferred to the MDL.
- 5. Pursuant to Rule 7.5(c) of the Rules of Procedure of the Judicial Panel on Multidistrict Litigation ("R.P.J.P.M.D.L."), GSK provided notice to the JPML of the pendency of this "tag-along" action on July 3, 2013.
- 6. On July 9, 2013, the JPML issued Conditional Transfer Order ("CTO"), CTO 172, conditionally transferring this case to the Avandia MDL.
- 7. Prior to GSK's removal of this action on July 2, 2013, GSK had not been served with the Complaint. Defendant McKesson has also not been served with the Complaint. GSK and McKesson (collectively, "Defendants") have not yet answered the Complaint. GSK filed a Motion to Stay on July 10, 2013. Plaintiffs filed a Motion to Remand on July 12, 2013.
- All parties, having met and conferred, pursuant to Civil L.R 6-3, jointly stipulate to and respectfully request that this Court extend the time for Defendants to Answer the Complaint until 30 days after entry of an order on Plaintiffs' Motion to Remand.
- 9. The parties agree that good cause exists for the requested extension of time in order to serve the interests of judicial economy, efficiency, and fairness. The JPML has already issued a CTO in this matter, which has been timely opposed by Plaintiffs. Therefore this action will either be Case No. 3:13-cv-03047-SI

remanded to the Superior Court of San Francisco or transferred to the Avandia MDL. Therefore, in order to conserve the resources of the Court and the parties, all parties agree that the Defendants' Answers should ultimately be filed in the San Francisco Superior Court or the Avandia MDL.

- 10. No party to this case has previously requested any time modifications in this action.
- 11. Therefore, because this action is unlikely to remain before this Court, the requested relief would not cause any undue hardship, delay, or prejudice to either party or the Court and is warranted by the circumstances in this case.

I declare under penalty of perjury under the laws of the United States that the foregoing is true and correct.

DATED: July 17, 2013

/s/ Steven J. Boranian
Steven J. Boranian

Case No. 3:13-cv-03047-SI